Bioventus Inc. logo

Bioventus Inc. (BVS)

Market Closed
18 Jul, 19:22
NASDAQ (NGS) NASDAQ (NGS)
$
6. 29
-0.2
-3.08%
$
462.51M Market Cap
- P/E Ratio
0% Div Yield
50,038 Volume
- Eps
$ 6.49
Previous Close
Day Range
6.26 6.52
Year Range
6.02 14.38
Want to track BVS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 18 days
Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.

Seekingalpha | 2 months ago
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.

Zacks | 2 months ago
4 Healthcare Stocks to Buy as the Sector Faces Government Heat

4 Healthcare Stocks to Buy as the Sector Faces Government Heat

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

Zacks | 3 months ago
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks | 3 months ago
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 4 months ago
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Seekingalpha | 4 months ago
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.

Benzinga | 4 months ago
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

Zacks | 4 months ago
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business

BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business

Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.

Zacks | 6 months ago
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?

Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?

Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Zacks | 6 months ago
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet

Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 7 months ago
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript

Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Senior Vice President and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - J.P. Morgan Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Bioventus Third Quarter 2024 Earnings Conference Call.

Seekingalpha | 8 months ago
Loading...
Load More